Date Posted:
2019-06-03
The TITAN clinical trial has demonstrated that the addition of apalutamide to androgen-deprivation therapy significantly improved radiographic progression-free survival and overall survival in patients with metastatic castration-sensitive prostate cancer. These results were presented by Dr. Kim Chi at ASCO on May 31, and were written up on ASCO Daily News on June 1. Dr. Chi is first author on the study which was published in the New England Journal of Medicine on May 31.
